Abiomed, Inc. (NASDAQ: ABMD) today announced the showcase of its advanced circulatory support systems including the AbioCor at the International Society for Heart and Lung Transplantation (ISHLT) 2007 Annual Meeting being held in San Francisco from April 25-28. Abiomed will occupy booth #107 at the meeting.
During ISHLT, the following presentations on Abiomed’s technology will be available:
- “Clinical Experience with the AB5000 as a Bridge-to-Transplant Ventricular Assist Device (VAD): Successful Cross-Over for Extended Bridge-to-Recovery Patients,” publication number 100, by Dr. John Elefteriades, Yale-New Haven Hospital.
- “Is Native Cardiac Recovery Sustainable Following Successful Ventricular Assist Device Support in Cardiogenic Shock Post Acute Myocardial Infarction?” publication number 99, by Dr. Mark Anderson, Robert Wood Johnson University Hospital and UMDNJ-Robert Wood Johnson Medical School.
- “Are Bridge to Recovery Patients Sick Enough to Require Ventricular Assist Device in Refractory Acute Myocardial Infarction Cardiogenic Shock?: Benchmark Against the SHOCK Trial,” publication number 101, by Dr. Mark Anderson.
- In addition, a satellite symposium on New Mechanical Circulatory Support, being held from 8-10 AM on April 25, will include Dr. Robert D. Dowling, professor of surgery at the University of Louisville/ Jewish Hospital in Louisville, KY, presenting on the AbioCor artificial heart; and Dr. Bartley Griffith, from the University of Maryland Medical Center, presenting on Abiomed’s Impella technologies.
More information on ISHLT can be found at www.ishlt.org.
ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc., is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. Abiomed currently manufactures and sells the AB5000™ Circulatory Support System and the BVS® 5000 Biventricular Support System for the temporary support of all patients with failing but potentially recoverable hearts. The Company also developed the AbioCor® Implantable Replacement Heart. In Europe, Abiomed offers the Impella® 2.5, Impella® 5.0, Impella® LD, the Impella® RD and an Intra-Aortic Balloon under CE Mark approval. The Impella® 5.0 and 2.5 are investigational devices limited by Federal Law solely to investigational use in the United States. Other Impella devices and the iPulse™ combination console system are not yet available for sale in the United States. For additional information please visit: www.abiomed.com.
FORWARD-LOOKING STATEMENTS
This Release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including its most recently filed quarterly report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.
